Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines Journal Article

  

Authors:	Comen, E.; Fornier, M.
Article Title:	Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines
Abstract:	At present, metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient's duration and quality of life. Treatment options for a patient with MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, including trastuzumab and bevacizumab, are available. The option to use novel agents combined with a multitude of standard chemotherapies has further enhanced the landscape of therapeutic options. As such, specific regimens must be evaluated within the framework of the individual patient, answering such questions as whether to treat with sequential single agents or combination regimens as well as which agents to use and in what sequence. The concept of personalized care is even more apparent in the setting of MBC, where the goal of palliation is intrinsically more nuanced than that of curative intent. This review will broadly assess the evidence for current treatment options with attention to varying clinical scenarios. Ultimately, delivering quality of care necessitates balancing an understanding of evidence-based data with sensitive attention to quality-of-life goals.
Keywords:	cancer survival; treatment outcome; unclassified drug; constipation; drug tolerability; fatigue; neutropenia; review; bevacizumab; doxorubicin; fluorouracil; advanced cancer; cancer combination chemotherapy; diarrhea; hypertension; monotherapy; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; methotrexate; evidence based medicine; carboplatin; quality of life; breast cancer; nausea; neuropathy; vomiting; myalgia; ovariectomy; peripheral neuropathy; breast neoplasms; algorithms; docetaxel; arthralgia; cancer hormone therapy; injection site reaction; loading drug dose; health care quality; goserelin; algorithm; tamoxifen; nausea and vomiting; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; hyperbilirubinemia; taxoids; taxane derivative; trastuzumab; navelbine; anthracycline; breast metastasis; hand foot syndrome; anthracyclines; aromatase inhibitors; wound healing impairment; breast carcinogenesis; epistaxis; proteinuria; lapatinib; drug exposure; her2; ixabepilone; olaparib; endocrine therapy; hormone-resistant/hormone- negative disease; iniparib
Journal Title:	Clinical Breast Cancer
Volume:	10
Issue:	Suppl. 2
ISSN:	1526-8209
Publisher:	Elsevier Inc.
Date Published:	2010-09-01
Start Page:	S7
End Page:	S19
Language:	English
DOI:	10.3816/CBC.2010.s.008
PUBMED:	20805067
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77956333064&partnerID=40&md5=dd3862c2e52e0de24ce68e4493a8ce21
Notes:	--- - "Export Date: 20 April 2011" - "CODEN: CBCLB" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/3908